Implant Device Helps Many Untreatable Epilepsy Patients
WebMD News Archive
Sept. 27, 2000 -- A new device implanted in the chest of epilepsy patients -- adults as well as children -- can greatly reduce seizures in some patients, even those who have not responded to anti-epilepsy drugs, according to two separate studies.
The device, called a vagus nerve stimulator, "is as good or better than most existing anti-epileptic drugs," says Christopher DeGiorgio, MD, the lead author of one of the studies. "It's permanent, and the nice thing is that it doesn't cause any medication side effects. It doesn't make patients drowsy or slow down their thinking processes." DeGiorgio is vice-chairman of neurology at the UCLA School of Medicine.
Epilepsy is a brain disorder characterized by sudden, unpredictable, abnormal electrical discharges that produce changes in behavior and bodily functions. The changes can range from a momentary loss of awareness to full body convulsions, also called seizures. The causes of the disease vary; some cases occur due to injuries or chemical disorders, while other forms of the disease are inherited. An estimated 2.5 million Americans suffer from epilepsy.
In many patients, epilepsy can be controlled through the use of one or more anti-epilepsy drugs. Other patients can benefit from surgery to remove the part of the brain that is causing the seizures. But for patients whose epilepsy is not well controlled by drugs and who are not candidates for surgery, the vagus nerve stimulation device offers another possibility for getting seizures under control.
The vagus nerve stimulation device is implanted in the chest and gives off electrical impulses to the vagus nerve. Although the mechanism by which it works is not well understood, it is believed that the device blocks certain brain impulses that direct the body to start a seizure.
In the study by DeGiorgio and colleagues, almost 200 patients had the vagus nerve stimulation devices implanted and then were followed up for one year.
In the study, published in the September issue of Epilepsia, 35% of the patients had over a 50% reduction in their seizures, and 20% of patients had over a 75% reduction.